Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Feb 8;294(6):2191.
doi: 10.1074/jbc.L119.007381.

Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent

Siang-Boon Koh  1
Affiliations
Comment

Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent

Siang-Boon Koh. J Biol Chem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares that he has no conflicts of interest with the contents of this article.

Comment in

Comment on

References

    1. Warren N. J. H., and Eastman A. (2019) Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe. J. Biol. Chem. 294, 1763–1778 10.1074/jbc.RA118.005231 - DOI - PMC - PubMed
    1. Mini E., Nobili S., Caciagli B., Landini I., and Mazzei T. (2006) Cellular pharmacology of gemcitabine. Ann. Oncol. 17, Suppl. 5, v7–v12 10.1093/annonc/mdj941 - DOI - PubMed
    1. Plunkett W., Huang P., Xu Y. Z., Heinemann V., Grunewald R., and Gandhi V. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 22, 3–10 - PubMed
    1. Koh S.-B., Courtin A., Boyce R. J., Boyle R. G., Richards F. M., and Jodrell D. I. (2015) CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus. Cancer Res. 75, 3583–3595 10.1158/0008-5472.CAN-14-3347 - DOI - PubMed
    1. Koh S.-B., Wallez Y., Dunlop C. R., Bernaldo de Quirós Fernández S., Bapiro T. E., Richards F. M., and Jodrell D. I. (2018) Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine. Cancer Res. 78, 3054–3066 10.1158/0008-5472.CAN-17-3932 - DOI - PMC - PubMed

LinkOut - more resources